Table 1.
Clinical characteristics of head and neck squamous carcinoma (TCGA).
| Characteristic | Low expression of SLC2A3 | High expression of SLC2A3 | p |
|---|---|---|---|
| n | 251 | 251 | |
| T stage, n (%) | 0.034 | ||
| T1 | 23 (4.7%) | 10 (2.1%) | |
| T2 | 77 (15.8%) | 67 (13.8%) | |
| T3 | 60 (12.3%) | 71 (14.6%) | |
| T4 | 80 (16.4%) | 99 (20.3%) | |
| N stage, n (%) | 0.053 | ||
| N0 | 129 (26.9%) | 110 (22.9%) | |
| N1 | 41 (8.5%) | 39 (8.1%) | |
| N2 | 63 (13.1%) | 91 (19%) | |
| N3 | 2 (0.4%) | 5 (1%) | |
| M stage, n (%) | 0.029 | ||
| M0 | 231 (48.4%) | 241 (50.5%) | |
| M1 | 5 (1%) | 0 (0%) | |
| Clinical stage, n (%) | 0.016 | ||
| Stage I | 13 (2.7%) | 6 (1.2%) | |
| Stage II | 51 (10.5%) | 44 (9%) | |
| Stage III | 59 (12.1%) | 43 (8.8%) | |
| Stage IV | 118 (24.2%) | 154 (31.6%) | |
| Radiation therapy, n (%) | 0.823 | ||
| No | 78 (17.7%) | 76 (17.2%) | |
| Yes | 150 (34%) | 137 (31.1%) | |
| Gender, n (%) | 0.267 | ||
| Female | 73 (14.5%) | 61 (12.2%) | |
| Male | 178 (35.5%) | 190 (37.8%) | |
| Age, n (%) | 0.098 | ||
| ≤60 | 132 (26.3%) | 113 (22.6%) | |
| >60 | 118 (23.6%) | 138 (27.5%) | |
| Histologic grade, n (%) | < 0.001 | ||
| G1 | 44 (9.1%) | 18 (3.7%) | |
| G2 | 149 (30.8%) | 151 (31.3%) | |
| G3 | 48 (9.9%) | 71 (14.7%) | |
| G4 | 2 (0.4%) | 0 (0%) | |
| Smoker, n (%) | 0.213 | ||
| No | 62 (12.6%) | 49 (10%) | |
| Yes | 185 (37.6%) | 196 (39.8%) | |
| Alcohol history, n (%) | 0.305 | ||
| No | 84 (17.1%) | 74 (15.1%) | |
| Yes | 159 (32.4%) | 174 (35.4%) | |
| Lymphovascular invasion, n (%) | 0.567 | ||
| No | 109 (32%) | 110 (32.3%) | |
| Yes | 56 (16.4%) | 66 (19.4%) | |
| Primary therapy outcome, n (%) | 0.181 | ||
| PD | 25 (6%) | 16 (3.8%) | |
| SD | 4 (1%) | 2 (0.5%) | |
| PR | 1 (0.2%) | 5 (1.2%) | |
| CR | 187 (44.7%) | 178 (42.6%) | |
| Age, meidan (IQR) | 60 (53, 68) | 62 (53, 69) | 0.141 |